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Sebaceous hyperplasia: a pilot study to correlate this skin
disease with circulating androgen levels 
Hiperplasia sebácea cutânea: estudo piloto para a correlação da doença com
hormônios androgênios
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Abstract: BACKGROUND: The sebaceous glands are susceptible to the effects of androgens.  A benign pro-
liferation of these hormones, i.e. hyperplasia, occurs with age.  
OBJECTIVES: This was a pilot study to demonstrate whether any correlation exists between circulating
androgen levels and an increase in the incidence of sebaceous hyperplasia.  
METHODS: Sixteen female patients with a diagnosis of sebaceous hyperplasia were compared to a control
group of females of a similar age without the disease.  Blood tests were performed on participants of
both groups to measure circulating androgen levels (free and total testosterone and androstenedione
levels).  Results were tabulated for statistical analysis.  
RESULTS: These data showed no statistically significant differences in circulating androgen levels between
the patients with sebaceous hyperplasia and the control group.  
CONCLUSIONS: These data suggest that no significant changes occur in circulating androgen levels [free
and total testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulfate] in
patients with sebaceous hyperplasia. 
Keywords: Hormones; Hormones, hormone substitutes, and hormone antagonists; Hyperplasia;
Sebaceous glands
Resumo: FUNDAMENTOS: As glândulas sebáceas são suscetíveis à ação dos hormônios androgênios e apre-
sentam proliferação benigna com a idade, ou seja, hiperplasia. 
OBJETIVOS: Estudo piloto para verificar se há correlação entre a taxa de hormônios masculinos circu-
lantes e o aumento da incidência da hiperplasia das glândulas sebáceas. 
MÉTODOS: 16 pacientes do sexo feminino, com diagnóstico de hiperplasia sebácea cutânea, foram com-
parados a um grupo-controle de mesmo gênero e idades semelhantes, sem a doença. Ambos os grupos
foram submetidos a testes de dosagem sanguínea para avaliação das taxas de hormônios androgênios
circulantes (testosterona livre e total, androstenediona). Os resultados foram tabulados e analisados
estatisticamente. 
RESULTADOS: Os dados demonstraram não haver mudanças nos níveis de hormônios masculinos circu-
lantes dos pacientes com hiperplasia sebácea cutânea, quando comparados ao grupo-controle. 
Conclusões: Os dados sugerem que não há alterações estatisticamente significantes nas taxas dos hor-
mônios circulantes (testosterona livre e total, androstenediona, deidroepiandrosterona, sulfato de dei-
droepiandrosterona) dos pacientes com hiperplasia sebácea cutânea. 
Palavras-chave: Glândulas sebáceas; Hiperplasia; Hormônios; Hormônios, substitutos de hormônios e
antagonistas de hormônios 
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INTRODUCTION
The sebaceous glands are an important site of
androgen activity. 1 They are susceptible to regulation
by the sex hormones and undergo changes in accor-
dance with alterations in hormone levels that occur
over an individualís lifetime.  Their size may increase
with age, although their number remains approxi-
mately the same. 2
The development and function of the seba-
ceous glands in the fetal-neonatal period are regulat-
ed by maternal androgens and the synthesis of
endogenous steroids, leading to an increase in seba-
ceous secretion shortly after birth.  A further peak
occurs at around 9 years of age, with these levels
being maintained up to approximately 17 years of age
when adult levels are reached.  In women, sebaceous
production tends to decrease following menopause,
whereas no major changes are found in men up to the
eighth decade of life. 1,3
Sebaceous hyperplasia may be considered a
benign proliferation of the sebaceous glands. 
4  
Studies
conducted in animal models or in vitro have shown
the effect of androgens in triggering this condition. 5-7
To the best of our knowledge, no studies have
been conducted in vivo to correlate the appearance
of sebaceous hyperplasia lesions in the skin of
patients with no other related comorbidities and
serum androgen levels.
Ultraviolet radiation and the use of
cyclosporine have been described as co-factors
responsible for triggering sebaceous hyperplasia, and
studies of familial cases have shown an autosomal
dominant inheritance with incomplete penetrance. 3,8
Clinically, sebaceous hyperplasia lesions affect
the face of elderly, white individuals, presenting as
raised, tumorous, rounded, salient but superficial
lesions of 2-5 mm in diameter that are yellowish or
flesh-colored.  They are principally located in the
sebaceous areas: on the frontal region and, less com-
monly, on the malar, nasal and temporal regions, as
well as on the neck and chest. 4,8 Although the condi-
tion is referred to as ìsenile sebaceous hyperplasiaî, it
may also occur in young people. 9-11
Diagnosis is generally clinical and can be con-
firmed by histopathology.  Dermoscopy and confocal
microscopy may be useful in the clinical evaluation of
the patient, principally to differentiate in vivo
between sebaceous hyperplasia and basal cell carcino-
ma, its principal differential diagnosis. 4, 12-14
Tissue evaluation in cases of sebaceous hyper-
plasia, comparing the size of the different segments of
the pilosebaceous unit with sebaceous hyperplasia,
shows a clear increase in the diameter of the sebaceous
acini, as well as a greater number of immature sebo-
cytes and dilatation of the follicular infundibulum. 15
At immunohistochemistry, cytokeratin-14 (CK-
14) expression was found in the keratinocytes of the
infundibulum, the isthmus and the sebaceous duct,
and in both mature and immature sebocytes; CK-1
expression was found in the infundibular ker-
atinocytes, CK-17 expression in the keratinocytes of
the sebaceous duct and an increase in the Ki-67 cell
proliferation marker (MIB-1) in the immature sebo-
cytes.  Expression of cytokeratins CK-18 and CK-19
was not detected. 15
Numerous forms of treatment have been
described for sebaceous hyperplasia. These include
systemic isotretinoin, photodynamic therapy with
methyl aminolevulinate or aminolevulinic acid, oral
administration of a 5-lipoxygenase inhibitor
(ZileutonÆ), which acts by directly decreasing seba-
ceous production, the use of lasers such as the laser
diode, pulsed dye laser (PDL) and erbium. Other pro-
cedures that have also been used include excision,
electrocauterization, cryotherapy, shaving, curettage
and cauterization with chemical agents used topically,
although there is a risk of depigmentation or scarring
with these latter options. 16-25
Many laboratory studies have shown the effect
of androgens on the sebaceous glands.  A review of
the literature on several research models confirmed
the effect of androgens in triggering the activity of the
sebaceous glands and indicated which of these hor-
mones may be implicated in triggering these glands.
The association between sebaceous hyperplasia
and androgens was confirmed in a study conducted in
rats in which this condition was induced by increasing
testosterone levels. 6
Additionally, genetically mutant rats were used
in a study model of sebaceous hyperplasia conducted
to evaluate whether increased sebum secretion and
sebaceous hyperplasia are androgen-dependent.  The
effects of inhibitors of steroid 5-alpha-reductase type I
and type II and an androgen receptor blocker on the
regression of hyperplasia were evaluated.  The three
agents were administered to rats; however, the con-
trol group and the castrated rats received only the
vehicle.  The androgen receptor blocker induced
regression equivalent to that found in the castrated
rats, thus confirming its efficacy in suppressing seba-
ceous gland development, while only a moderate
reduction was achieved in the gland with the type I
and type II steroid inhibitors. 7 It should be empha-
sized that no statistically significant changes were
found in serum testosterone or dihydrotestosterone
(DHT) levels in the rats treated with the drugs. 7
Another study was conducted to evaluate the
effect of DHT in sebaceous production.  This study
was carried out in adult men with inherited 5-alpha-
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reductase 2 deficiency (pseudohermaphroditism),
therefore with a consequent decrease in dihy-
drotestosterone. The reduction in DHT was shown to
have no effect on the development or function of the
sebaceous glands, since sebaceous production was
found to be normal in these subjects. 2
A study was conducted in oophorectomized
female rats to evaluate the effect of another androgen,
dehydroepiandrosterone (DHEA), on the skin seba-
ceous glands.  A DHEA precursor was administered to
a group of oophorectomized rats, while other groups
of female rats that had also been oophorectomized
were concomitantly treated with DHEA alone or in
combination with antiandrogens or antiestrogens
with the objective of determining the estrogenic or
androgenic effects of DHEA. The appearance of seba-
ceous hyperplasia was noted in the oophorectomized
rats treated with DHEA; however, in the rats using the
antiandrogen, this change induced by DHEA in the
sebaceous gland was inhibited, while no effect was
obtained with the antiestrogen.  These data show the
exclusively androgenic effect of DHEA in stimulating
the glands. 26
In the field of research involving the sebaceous
glands, studying the human sebocyte culture model is
considered fundamental in clarifying the activity of the
sebaceous gland, since these glands are exclusive to
each species.  The culture model is able to show that
hormonal control of the sebaceous gland consists of a
complex mechanism, in which not only androgens
have a stimulating effect on the activity of the sebo-
cytes in vitro but also other hormones such as insulin,
thyroid hormone and hydrocortisone. 27 
MATERIAL AND METHODS
This was a single-center, prospective, observa-
tional, pilot clinical trial, approved by the internal
review board of the Federal University of São Paulo
(UNIFESP), in which 16 female volunteers over 18
years of age with facial sebaceous hyperplasia were
selected either from the dermatology clinic of the
same institute or from another collaborating service
during the second semester of 2006.   These patients
had to be able to read, understand and sign a copy of
the informed consent form approved for this study
and were provided with a copy of the form.  Women
in use of any medication that could interfere with the
results of hormone measurement and women with
any known hormonal changes at the time of enroll-
ment or who had any comorbidity that could interfere
with the evaluation and clinical inference of the
patient were excluded from the study.
In each patient, a biopsy was performed on a
lesion clinically diagnosed as sebaceous hyperplasia
and the material was sent for histopathological confir-
mation of the diagnosis of the disease under evalua-
tion.  Next, the patients were referred for blood sam-
pling to measure the hormones that constitute the
androgen cascade: dehydroepiandrosterone (DHEA),
total testosterone (TT), free testosterone (FT),
androstenedione and dehydroepiandrosterone sulfate
(DHEA-S). 28
In parallel, 16 volunteers without any seba-
ceous hyperplasia lesions and of a similar age to the
women in the study group were paired, one to one,
with a patient from the study group (Table 1).
These volunteers were selected at random at
the same sites at which the women in the study group
were recruited while attending routine consultations.
This group of women also answered a questionnaire
on comorbidities and medication.  Except for the
condition under evaluation, all other inclusion and
exclusion criteria were applied and all the women
were referred to the same laboratory for hormone
measurement.
All the data from both groups were recorded
and analyzed statistically.  Due to the small sample size
and the low incidence of abnormality found in the
two groups, Fisherís exact test was used to compare
the groups with respect to normal hormone profiles.
The non-parametric Mann-Whitney (or Wilcoxon) test
was used to compare the median hormone levels in
the two groups, since the distribution of hormone lev-
els was not close to normal (Gaussian).
RESULTS
Sixteen female patients with sebaceous hyper-
plasia lesions were analyzed, together with their
respective controls of the same gender and a similar
age.  Mean age was 53.5 years (range 40-67 years).  No
changes were found in the DHEA levels of the 16
patients in the study group; however, a 50-year old
woman in the control group had low levels of this hor-
mone, 0.4 ng/ml, compared to the normal range of 0.8
to 10.5 ng/ml.
With respect to total testosterone, an increased
level of 392.00 ng/dl was found in a 40-year old
patient with sebaceous hyperplasia (normal range: <
20.00 to 118.00 ng/dl).  In the control group, there
was also a case of a higher level compared to the same
reference limits: 131.00 ng/dl.  Two patients in the
study group had increased free testosterone levels: a
41-year old patient with a measurement of 87.41
pmol/l and a 40-year old patient with a measurement
of 137.41 pmol/l (normal range: 2.40 ñ 45.0 pmol/l).
No changes were found in any patients in the control
group with respect to this hormone.
No changes in androstenedione were found in
any of the patients in the study group and only one
case with a decreased level was found in the control
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group: a 43-year old patient with a measurement of <
0.30 ng/ml compared to the normal range of 0.30 ñ
3.30 ng/ml.
Three cases were found in the study group in
which DHEA-S measurements were outside the nor-
mal range according to age (32.00 to 240.00 ºg/dl).  A
41-year old patient had an increased level of 269.10
ºg/dl and two other patients had decreased levels (a
46-year old patient with a measurement of 24.60 ºg/dl
and a 48-year old patient with a measurement of 30.50
ºg/dl).  In the control group, two decreased values
were found: a 50-year old woman with a DHEA-S level
Participant Age DHEA TT FT Androstenedione DHEA-S SHBG
(years) (ng/mL) (ng/dL) (pmol/L) (ng/mL) (µg/dL) (nmol/L)
Control 1 F - 66 1.9 54.10 34.07 2.24 25.20 29.00
Control 2 F - 42 2.3 <20.00 2.79 0.80 95.30 131.00
Control 3 F - 50 2.7 131.00 27.98 1.65 63.80 85.50
Control 4 F - 47 1.1 43.70 15.47 1.31 23.00 51.60
Control 5 F - 43 1.4 55.70 10.79 1.48 51.90 94.30
Control 6 F - 42 2.0 65.30 26.21 1.36 101.00 45.50
Control 7 F - 65 1.6 <20.00 4.86 0.64 18.20 75.20
Control 8 F - 43 3.7 25.50 9.74 1.79 204.00 47.80
Control 9 F - 56 1.1 27.50 20.33 0.40 31.60 24.70
Control 10 F - 40 2.8 51.80 10.89 1.86 75.70 86.90
Control 11 F - 62 2.3 43.30 29.84 1.28 118.00 26.50
Control 12 F - 50 2.3 28.10 8.94 1.29 107.00 57.40
Control 13 F - 51 1.6 <20.00 7.47 0.43 30.10 48.90
Control 14 F - 43 1.0 <20.00 12.87 <0.3 135.00 31.30
Control 15 F - 50 0.4 24.40 24.35 0.57 <15.00 18.30
Control 16 F - 52 3.1 37.80 23.64 0.71 32.50 29.20
SH 1 F - 67 1.3 49.00 44.11 0.68 24.10 18.60
SH 2 F - 41 5.0 33.50 15.22 1.39 150.00 40.20
SH 3 F - 48 5.3 62.00 16.80 2.21 55.50 67.40
SH 4 F - 48 3.4 34.50 15.63 2.22 115.00 40.30
SH 5 F - 44 2.7 77.60 11.52 1.99 97.10 123.00
SH 6 F - 41 3.6 111.00 87.41 3.02 269.00 22.90
SH 7 F - 60 2.7 45.30 22.92 1.23 75.90 36.10
SH 8 F - 46 0.9 36.80 16.93 0.98 24.60 39.70
SH 9 F - 56 1.7 89.20 27.85 1.84 80.40 58.50
SH 10 F - 40 2.8 392.00 137.41 1.81 91.80 52.10
SH 11 F - 57 2.3 <20.00 26.66 1.08 26.90 13.70
SH 12 F - 48 1.6 48.30 12.41 1.40 30.50 71.10
SH 13 F - 56 1.6 24.50 7.64 1.30 49.60 58.60
SH 14 F- 45 2.3 26.20 13.29 1.31 65.20 36.00
SH 15 F - 53 1.6 33.20 6.00 1.18 36.90 101.00
SH 16 F - 54 0.8 40.10 12.56 0.57 52.10 58.30
TABLE 1: Identification of 32 individuals, 16 with sebaceous hyperplasia and 16 controls, and their serum 
hormone levels at the time of the study
SH = sebaceous hyperplasia
NB:  The following are the respective reference values:
DHEA = adult women: 0.8 to 10.5 ng/mL 
TT = in women, levels vary in accordance with the phase of the menstrual cycle; however, normal levels range from <20.00 to 188.00 ng/ml.
FT = women: 2.40 – 45.00 pmol/L
Androstenedione = women: 0.30 – 3.30 ng/mL
SHBG (sex hormone binding globulin) = women: 22.00 – 130.00 nmol/L 
DHEA-S = varies in accordance with the ranges shown below:
● Women of 20 - 29 years of age: 65.00 - 380.00 µg/dL
● Women of 30 - 39 years of age: 45.00 – 270.00 µg/dL
● Women of 40 – 49 years of age: 32.00 – 240.00 µg/dL
● Women of 50 - 59 years of age: 26.00 – 200.00 µg/dL
● Women of 60 - 69 years of age: < 130.00 µg/dL
● Women of 70 - 79 years of age: 17.00 – 90.00 µg/dL
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below 15.00 ºg/dl (normal range: 26.00-200.00 ºg/dl)
and a 47-year old patient with a measurement of
23.00 ºg/dl (normal range: 32.00-240.00 ºg/dl).
These results are summarized in Tables 1 and 2.
DISCUSSION
The sebaceous glands are susceptible to the
effect of androgens, with a benign proliferation of
these glands, i.e. hyperplasia, occurring with age.
Therefore, the onset of sebaceous hyperplasia with
advancing age may be explained by slower cell ren-
ovation in the glands secondary to a decline in
androgen levels. 1-4  Nevertheless, laboratory stud-
ies have reported a relationship between the
appearance of sebaceous hyperplasia lesions and
androgenic stimuli. 2,5,7,26
The effect of other factors such as genetic alter-
ations found in familial cases of sebaceous hyperplasia,
chronic exposure to solar radiation or factors related to
immunosuppression such as the use of cyclosporins
has yet to be fully clarified in the etiopathogenesis of
this sebaceous gland condition. 3,8,29,30
Hyperplasia is classified as a benign tumor.
Since it affects exposed areas such as the face, it is a
frequent cause of complaint in clinical dermatology;
however, for the dermatologist, the principal concern
is to differentiate between this condition and basal
cell carcinoma. 4,8,13,14
In order to study sebaceous hyperplasia, the
etiopathogenesis of which is yet to be established, the
present protocol was based on studies correlating the
appearance of sebaceous hyperplasia lesions with the
effect of androgens. 2,5-7,26 In the present study, serum
androgen levels were evaluated in female patients
with sebaceous hyperplasia in order to analyze
whether changes occur in the levels of these hor-
mones in patients with this skin disease.
A literature review revealed various studies on
the effect of androgens in stimulating the sebaceous
gland, principally the effect of DHEA; however, most
consisted of in vitro studies conducted using human
sebocyte culture, studies involving animal models or
evaluations in humans with known hormonal
changes.  To the best of our knowledge, no studies
had yet been conducted using serum androgen meas-
urements in individuals with sebaceous hyperplasia
lesions and with no known hormonal changes. 2,5-7,26
The studies identified in this review showed the
effect of androgens on the sebaceous glands.  The
effects of androgens in triggering hyperplasia of the
sebaceous glands were reported in a study using an
animal model in which an androgen-stimulating sub-
stance was administered.  Some investigators have
shown that blocking the androgenic effect leads to
consequent suppression of the growth of the seba-
ceous glands. 6,7
Conducted to identify which hormones were
involved in inducing sebaceous hyperplasia, some
studies were able to confirm that reducing DHT has
no effect on the development of the sebaceous gland
or its function in sebaceous production; however,
they confirmed the androgenic effect of DHEA in trig-
gering sebaceous hyperplasia. 2,7,26
The present study evaluated a group of women
with sebaceous hyperplasia and another group with-
out the disease, none of whom had any previously
known hormonal changes or were in use of exoge-
nous hormones.  The two groups, composed of
women of a similar age, were compared and no asso-
ciation was found between the hormonal conditions
diagnosed during the study [changes in serum andro-
gen levels (DHEA, DHEA-S, TT, FT, androstenedione)]
and the onset of sebaceous hyperplasia lesions in this
sample. Thus far, despite the fact that the appropriate
statistical tests for the sample size were applied, no
statistically significant differences were found in the
measurements of any of the androgens studied
between the patients with sebaceous hyperplasia and
the control group (Table 2).
Therefore, although a strong effect of andro-
gens in stimulating the sebaceous gland has been
shown in various laboratory studies, when the hor-
Hyperplasia (n=16) Control (n=16)
Hormones Number of abnormal results Number of abnormal results 
DHEA 0 1 p >0.05
Total testosterone 1 1 p >0.05
Free testosterone 2 0 p >0.05
Androstenedione 0 1 p >0.05
DHEA-S 3 2 p >0.05
TABLE 1: Comparison of the abnormal results obtained in the measurement of the hormones evaluated (free
testosterone, total testosterone, androstenedione, DHEA and DHEA-S) in the 16 individuals with sebaceous
hyperplasia and 16 controls
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mone levels of patients with sebaceous hyperplasia
lesions were evaluated, no statistically significant dif-
ferences were found in comparison to a control group
of women without the disease.
The results of this pilot study suggest that skin
lesions may occur in sebaceous hyperplasia due to: 1)
increased sensitivity of hormone receptors in the
sebaceous glands; or 2) a delayed consequence of
exposure of the sebocytes to the normal effect (both
quantitatively and qualitatively) of circulating andro-
gens throughout the individualís lifetime; or 3) indi-
vidual or genetic predisposition (not hormone-
dependent). Moreover, it suggests that hormone
dependency only exists in experimental models.
Nevertheless, further studies should be conducted
with larger sample sizes to correlate clinical and labo-
ratory findings, both hormonal and biomolecular, in
order to fully clarify these findings.
CONCLUSION
Although the physiopathogenesis of sebaceous
hyperplasia is associated with hormonal effects, in the
present sample in which women with sebaceous
hyperplasia were compared with women of a similar
age without the condition, no association was found
between serum hormone levels and the appearance of
sebaceous hyperplasia lesions.   Further studies with
larger sample sizes should be conducted to correlate
clinical and laboratory findings (hormonal and bio-
molecular) in order to reach a final conclusion on this
skin disorder. ❑
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